36 results
Thumbnail

D1.414 - The Clinical Course in a normal C1-Inhibitor Hereditary Angioedema family with Factor XII mutation

Thumbnail

D1.416 - Regulatory T Cells Induced by B cells Decreased Osteoclast Activity and Alleviated Disease Severity of Collagen Antibody Induced Arthritis

Thumbnail

D1.418 - An EBP Gene Variant in a Child with Immunodeficiency: A Case from the Chondrodysplasia Pontata Spectrum

Thumbnail

D1.419 - The management of Immunological Diseases in Internal Medicine Departments

Thumbnail

D1.420 - Lymphoma in CVID: on the edge between immune dysregulation and malignancy

Thumbnail

D1.404 - Live Renal Transplantation Outcome in Egyptian Cohort: A Single Center Study

Thumbnail

D1.405 - Establishment of a Mouse Nasal Epithelial Cell Air–Liquid Interface Culture System and Its Application in Mucosal Barrier Research

Thumbnail

D1.407 - Real-world patient characterization, prior long-term prophylactic prescribing patterns, and treatment outcomes for adults on berotralstat with hereditary angioedema in Japan

Thumbnail

D1.409 - Regulation of the intestinal epithelial barrier by the endocannabinoid system

Thumbnail

D1.413 - A Novel Variant of CORO1A Gene Contributing to The Development of Primary Immunodeficiency in Children

Thumbnail

D1.415 - Regulatory T‑Cell Deficiency and NF‑κB/IL‑1β Activation in Dilated Cardiomyopathy

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial